Board change at Silence Therapeutics (NASDAQ: SLN) as director exits

Rhea-AI Filing Summary

Silence Therapeutics plc reported that Michael Davidson resigned from its board of directors on August 11, 2025, stepping down immediately from the Board and from the Audit and Risk, Remuneration, and Science & Technology Committees. The company states that he left to focus on other time commitments, including his role as Chief Executive Officer of NewAmsterdam Pharma Company N.V., and that his resignation was not due to any disagreement with the company, its management, or the Board.

After his departure, the Board reduced its size from five to four directors. The Board also appointed its chairman, Iain Ross, to the Audit and Risk Committee to fill the vacancy created by Dr. Davidson’s resignation, maintaining coverage of this key governance function.

00-0000000 false 0001479615 true 0001479615 2025-08-11 2025-08-11 0001479615 dei:AdrMember 2025-08-11 2025-08-11 0001479615 us-gaap:CommonStockMember 2025-08-11 2025-08-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2025

Silence Therapeutics plc

(Exact name of registrant as specified in its charter)

England and Wales		001-39487		Not Applicable
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

72 Hammersmith Road London United Kingdom		W14 8TH
(Address of principal executive offices)		(Zip Code)

+44 20 3457 6900

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
American Depositary Shares, each representing 3 ordinary shares, nominal value £0.05 per share		SLN		The Nasdaq Stock Market LLC
Ordinary share, nominal value £0.05 per share*		*		The Nasdaq Stock Market LLC

* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Director

On August 11, 2025, Michael Davidson notified the board of directors (the “Board”) of Silence Therapeutics plc (the “Company”) of his decision to resign from the Board, effective immediately. He also resigned as a member of each of the Board’s Audit and Risk Committee, Remuneration Committee, and Science & Technology Committee. Dr. Davidson resigned in order to focus on his other time commitments, including his service as Chief Executive Officer of NewAmsterdam Pharma Company N.V., and not because of any disagreement with the Company, its management, or the Board. The Board thanks Dr. Davidson for his years of service and valuable contributions to the Company.

Following Dr. Davidson’s resignation, the Board reduced the size of the Board from five (5) to four (4) directors. The Board also appointed Iain Ross, the chairman of the Board, as a member of the Audit and Risk Committee, to fill the vacancy created by Dr. Davidson’s departure.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				SILENCE THERAPEUTICS PLC
Dated: August 14, 2025				By:		/s/ Craig Tooman
				Name:		Craig Tooman
				Title:		President and Chief Executive Officer

FAQ

What board change did Silence Therapeutics (SLN) disclose?

Silence Therapeutics plc disclosed that Michael Davidson resigned from its board of directors on August 11, 2025, and left all of his board committee roles.

Why did Michael Davidson resign from the Silence Therapeutics board?

The company reports that Dr. Davidson resigned to focus on his other time commitments, including serving as Chief Executive Officer of NewAmsterdam Pharma Company N.V., and not because of any disagreement with the company, its management, or its board.

How did Silence Therapeutics adjust its board size after the resignation?

Following Dr. Davidson’s resignation, the board of Silence Therapeutics plc reduced its size from five to four directors.

Who replaced Michael Davidson on the Audit and Risk Committee at Silence Therapeutics?

The board appointed Iain Ross, the chairman of the board, as a member of the Audit and Risk Committee to fill the vacancy created by Dr. Davidson’s departure.

Did Michael Davidson have any disagreement with Silence Therapeutics or its management?

No. The company states that Dr. Davidson’s resignation was not due to any disagreement with Silence Therapeutics, its management, or its board of directors.

What committees did Michael Davidson leave at Silence Therapeutics?

Dr. Davidson resigned from the Audit and Risk Committee, the Remuneration Committee, and the Science & Technology Committee in addition to leaving the board.